346 related articles for article (PubMed ID: 17605463)
1. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.
Wang Y; Nakamura K; Liu X; Kitamura N; Kubo A; Hnatowich DJ
Bioconjug Chem; 2007; 18(4):1338-43. PubMed ID: 17605463
[TBL] [Abstract][Full Text] [Related]
2. Cell culture and xenograft-bearing animal studies of radiolabeled antisense DNA carrier nanoparticles with streptavidin as a linker.
Nakamura K; Wang Y; Liu X; Kubo A; Hnatowich DJ
J Nucl Med; 2007 Nov; 48(11):1845-52. PubMed ID: 17978353
[TBL] [Abstract][Full Text] [Related]
3. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In.
Liu X; Wang Y; Nakamura K; Kawauchi S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
J Nucl Med; 2009 Apr; 50(4):582-90. PubMed ID: 19289423
[TBL] [Abstract][Full Text] [Related]
4. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles.
Wang Y; Liu X; Nakamura K; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2009 Oct; 24(5):573-8. PubMed ID: 19877887
[TBL] [Abstract][Full Text] [Related]
5. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery.
Liu X; Wang Y; Nakamura K; Kubo A; Hnatowich DJ
Cancer Gene Ther; 2008 Feb; 15(2):126-32. PubMed ID: 18084241
[TBL] [Abstract][Full Text] [Related]
6. A nanoparticle for tumor targeted delivery of oligomers.
Liu X; Wang Y; Hnatowich DJ
Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635
[TBL] [Abstract][Full Text] [Related]
7. Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle.
Wang Y; Liu X; Chen L; Cheng D; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1977-86. PubMed ID: 19572130
[TBL] [Abstract][Full Text] [Related]
8. A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells.
Albarran B; To R; Stayton PS
Protein Eng Des Sel; 2005 Mar; 18(3):147-52. PubMed ID: 15820981
[TBL] [Abstract][Full Text] [Related]
9. Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation.
Liu Y; Cheng D; Liu X; Liu G; Dou S; Xiao N; Chen L; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2012 Jan; 39(1):101-7. PubMed ID: 21958854
[TBL] [Abstract][Full Text] [Related]
10. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
Tseng CL; Su WY; Yen KC; Yang KC; Lin FH
Biomaterials; 2009 Jul; 30(20):3476-85. PubMed ID: 19345990
[TBL] [Abstract][Full Text] [Related]
11. Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle.
Liu X; Nakamura K; Wang Y; Cheng D; Liang M; Xiao N; Chen L; Rusckowski M; Hnatowich DJ
J Biomed Nanotechnol; 2010 Apr; 6(2):153-7. PubMed ID: 20738069
[TBL] [Abstract][Full Text] [Related]
12. Construction of a novel chimera consisting of a chelator-containing Tat peptide conjugated to a morpholino antisense oligomer for technetium-99m labeling and accelerating cellular kinetics.
Zhang YM; Tung CH; He J; Liu N; Yanachkov I; Liu G; Rusckowski M; Vanderheyden JL
Nucl Med Biol; 2006 Feb; 33(2):263-9. PubMed ID: 16546682
[TBL] [Abstract][Full Text] [Related]
13. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
[TBL] [Abstract][Full Text] [Related]
14. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.
Moulton HM; Nelson MH; Hatlevig SA; Reddy MT; Iversen PL
Bioconjug Chem; 2004; 15(2):290-9. PubMed ID: 15025524
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
16. Biotinylated bionanocapsules for displaying diverse ligands toward cell-specific delivery.
Shishido T; Azumi Y; Nakanishi T; Umetsu M; Tanaka T; Ogino C; Fukuda H; Kondo A
J Biochem; 2009 Dec; 146(6):867-74. PubMed ID: 19710034
[TBL] [Abstract][Full Text] [Related]
17. Initial investigations of 99mTc-labeled morpholinos for radiopharmaceutical applications.
Mang'era KO; Liu G; Yi W; Zhang Y; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
Eur J Nucl Med; 2001 Nov; 28(11):1682-9. PubMed ID: 11702111
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.
Dinauer N; Balthasar S; Weber C; Kreuter J; Langer K; von Briesen H
Biomaterials; 2005 Oct; 26(29):5898-906. PubMed ID: 15949555
[TBL] [Abstract][Full Text] [Related]
19. Affinity enhancement bivalent morpholino for pretargeting: initial evidence by surface plasmon resonance.
He J; Liu G; Vanderheyden JL; Dou S; Mary R; Hnatowich DJ
Bioconjug Chem; 2005; 16(2):338-45. PubMed ID: 15769087
[TBL] [Abstract][Full Text] [Related]
20. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
Liu Y; Franzen S
Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]